STOCK TITAN

Endovia Health Sciences nine-month revenue under $10K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

Endovia Health Sciences, Inc. (EDVA) notified investors that it expects to file its Form 10-Q on or before the fifth calendar day following the prescribed due date. The company attributed the delay to limited personnel and resources and delays in reviewing and preparing its financial statements for the quarter ended September 30, 2026.

Revenue for the nine months ended September 30, 2026 was less than $10,000, compared with approximately $50,000 a year earlier, a stated decrease of $40,000. The company attributed the decrease to ending beverage sales and shifting its business model. It reported no revenue for the three months ended September 30 in either 2026 or 2025.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointNine-month revenue decreased by $40,000.

Filing Explained

The company says its review of continuing operations and the independent auditor’s procedures remain underway, so it cannot yet provide a reasonable quantitative estimate of anticipated changes in results.

Nine-month revenue Less than $10,000 Nine months ended September 30, 2026
Nine-month revenue Approximately $50,000 Nine months ended September 30, 2025
Nine-month revenue decrease $40,000 Nine months ended September 30, 2026 compared with the same period in 2025
Three-month revenue $0 in both periods Three months ended September 30, 2026 and September 30, 2025
Rule 12b-25 regulatory
"as required by Rule 12b-25 under the Securities Exchange Act of 1934"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.
continuing operations financial
"accounting review regarding its continuing operations"
Continuing operations are the parts of a company's business that it expects to keep running into the future, excluding divisions or activities it has sold, closed, or classified as discontinued. Investors watch continuing operations because they show the company’s core ability to generate revenue and profit over time — like evaluating the healthy, ongoing crops on a farm rather than one-off harvests from fields you've already sold.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does EDVA expect to file its 2026 third-quarter 10-Q?

Endovia expects to file its Form 10-Q on or before the fifth calendar day following the prescribed due date. It attributed the delay to limited personnel and resources and delays in reviewing and preparing the financial statements for the quarter ended September 30, 2026.

What revenue did EDVA report for the third quarter and first nine months of 2026?

EDVA reported no revenue for the three months ended September 30, 2026, or September 30, 2025. Revenue for the nine months ended September 30, 2026 was less than $10,000, compared with approximately $50,000 for the prior-year period; the company stated the decrease was $40,000.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

SEC FILE NUMBER 001-40471

CUSIP NUMBER 84862C401

 

 

    ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q
(Check one):   ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR
   
    For Period Ended: September 30, 2026
   
    ☐Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
    ☐ Transition Report on Form N-SAR
   
    For the Transition Period Ended:

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

Endovia Health Sciences, Inc.

Full Name of Registrant

 

1112 N. Flagler Drive

 

Address of Principal Executive Office (Street and Number)

 

Fort Lauderdale, Florida

33304

City, State and Zip Code

 

1

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

  (a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒ (b)   The subject annual report, semi-annual report, transition report on semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-CEN, N-CSR, or the transition report portion thereof could not be filed within the prescribed time period.

 

Endovia Health Sciences, Inc. (the “Company”) is unable to file the 10-Q Quarterly Report for the quarterly period ended September 30, 2026 (the “Form 10-Q”) in a timely manner without unreasonable effort or expense due to the Company’s limited personnel and resources, and the delay in review and preparation of financial statements for the quarter ended September 30, 2026. The Company expects to file the Form 10-Q on or prior to the 5th calendar day following the prescribed due date of the Quarterly Report, as required by Rule 12b-25 under the Securities Exchange Act of 1934.

 

Part IV - Other Information

 

  1. Name and telephone number of person to contact in regard to this notification

 

Martin Scott (954) 745-5815

 

(Name) (Area Code) (Telephone Number)

 

  2. Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

Yes ☒ No ☐

 

  3. Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

Yes ☒ No ☐

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

2

 

 

There were no revenues for the three months ended September 30, 2026 and September 30, 2025. Revenues for the nine months ended September 30, 2026 were less than $0.01 million compared to revenues of approximately $0.05 million for the nine months ended September 30, 2025. The $0.04 million decrease reflected a decrease in sales due to our cessation of beverage sales and the Company’s shift in its business model.

 

The Company is currently finalizing its accounting review regarding its continuing operations and because the Company’s accounting review and the independent auditor’s procedures remain ongoing, a reasonable quantitative estimate of anticipated changes cannot be made at this time without unreasonable effort or expense. 

 

3

 

 

Endovia Health Sciences, Inc.

(Name of Registrant as Specified in Charter)

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026 By: /s/ Martin Scott
    Martin Scott, Interim Chief Financial Officer

 

4

 

Keep reading